Alzheimers & Parkinsons
Alzheimer’s disease and Parkinson’s disease are two of the most prevalent neurodegenerative disorders, presenting significant challenges to both patients and healthcare providers. Ongoing research in Alzheimer’s aims to identify early biomarkers, improve diagnostic methods, and develop targeted therapies to slow disease progression.
- Track 5.1-Biomarkers in Alzheimer’s
- Track 5.2-Pathophysiology of Parkinson’s
- Track 5.3-Risk Reduction Strategies
- Track 5.4-Neuroinflammation in Alzheimer’s
- Track 5.5-Genetic Risk Factors
Parkinson’s disease management focuses on optimizing motor function through medication, surgical interventions, and rehabilitative therapies, while exploring novel treatments such as gene therapy and stem cell approaches. Advances in both fields are fostering new insights into disease mechanisms, ultimately paving the way for more effective treatments and improved quality of life for patients. These breakthroughs are critical to advancing care in the fight against neurodegeneration.